Galapagos N.V.
OTC: GLPGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Henry Gosebruch
- Employees
- 704
- Headquarters
- Mechelen, Belgium
- IPO year
- 2009
- Market cap
- $1.9B
- Website
- https://www.glpg.com
Loading GLPGF…
Loading profile data…Frequently asked questions about GLPGF
What does Galapagos N.V. (GLPGF) do?
Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipeline of investigational drugs, prominently featuring: Filgotinib: A potent JAK1 inhibitor, currently undergoing m...
Where does GLPGF trade?
Galapagos N.V. (GLPGF) trades on the Other OTC.
What sector is GLPGF in?
Galapagos N.V. (GLPGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Galapagos N.V.?
Henry Gosebruch is the chief executive officer of Galapagos N.V. (GLPGF).
Where is Galapagos N.V. headquartered?
Galapagos N.V. is headquartered in Belgium.
Does GLPGF pay a dividend?
Galapagos N.V. (GLPGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLPGF go public?
Galapagos N.V. (GLPGF) completed its initial public offering in 2009.